We are live on ! Find out more
ACIU icon

AC Immune

34 hedge funds and large institutions have $44.3M invested in AC Immune in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more call options, than puts

Call options by funds: $115K | Put options by funds: $90K

0.26% more ownership

Funds ownership: 16.52%16.78% (+0.26%)

3% less funds holding

Funds holding: 3534 (-1)

11% less capital invested

Capital invested by funds: $49.8M → $44.3M (-$5.52M)

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
34
Holders Change
-1
Holders Change %
-2.86%
% of All Funds
0.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
8
Reduced
9
Closed
5
Calls
$115K
Puts
$90K
Net Calls
+$25K
Net Calls Change
+$38K

ACIU Hedge Fund Activity: Q3 2022 in Review

34 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q3 2022, worth a combined $44.3M — down 11% from $49.8M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ACIU and 4 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 8 added.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $866K. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $532K sold.

  • 34 institutional investors held AC Immune (ACIU) as of Q3 2022, down from 35 in Q2 2022.
  • Funds reported $44.3M of AC Immune stock for Q3 2022, down 11% quarter-over-quarter.
  • 4 funds opened new AC Immune positions in Q3 2022 and 5 closed out, a net change of -1 holder.
  • The largest AC Immune buyer in Q3 2022 was Avidity Partners Management, an estimated $866K added.
  • The largest AC Immune seller in Q3 2022 was Assenagon Asset Management, an estimated $532K sold.

Based on aggregated 13F filings for Q3 2022.